What are the main risks
As Medicare coverage expansions in 2025 and 2026 extend GLP-1 drugs to millions of older Americans for the first time, researchers and clinicians are urging a different approach for this age group: more careful baseline assessment, slower dosing, higher protein targets, and proactive monitoring for muscle loss, malnutrition, and bone density decline
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists, widely prescribed for type 2 diabetes and weight management, are known for their metabolic benefits but may have unrecognized side effects
Jessica Duncan, Medical Director at Ivim Health and Diplomate of the American Board of Obesity Medicine
Take home message There are no known clinically significant interactions between Mounjaro and statins like atorvastatin
If you are already registered then use your registered email